CD37 immunotherapeutics and uses thereof
View Patent ↗The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B cell related autoimmune, inflammatory, or hyperproliferative diseases.
1. An isolated CD37-specific binding molecule, comprising the amino acid sequence as set forth in SEQ ID NO:253.
2. The CD37-specific binding molecule of claim 1 , consisting of the amino acid sequence set forth in SEQ ID NO:253.
3. A composition comprising a humanized CD37-specific binding molecule according to claim 1 and a pharmaceutically acceptable carrier.
4. A composition comprising a humanized CD37-specific binding molecule according to claim 2 and a pharmaceutically acceptable carrier.